Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randy S Schrecengost

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Cancer Letters|May 4, 2007
Pathways to tamoxifen resistanceRebecca B Riggins, Randy S Schrecengost, Michael S Guerrero, et al.
The Journal of Biological Chemistry|November 27, 2009
BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signalingNatasha R Schuh, Michael S Guerrero, Randy S Schrecengost, et al.
Cancer Research|November 1, 2008
A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cellsHuy Q Ta, Keena S Thomas, Randy S Schrecengost, et al.
Plos One|June 14, 2013
Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cellsAshley L Wilson, Randy S Schrecengost, Michael S Guerrero, et al.
Cancer Research|July 10, 2007
Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane rufflingRandy S Schrecengost, Rebecca B Riggins, Keena S Thomas, et al.
Cancers|May 11, 2024
Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma CellsLynn W Maines, Staci N Keller, Ryan A Smith, et al.
Molecular Cancer Research : MCR|August 15, 2015
Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer ProgressionRandy S Schrecengost, Staci N Keller, Matthew J Schiewer, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 16, 2004
Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1Kevin J French, Yan Zhuang, Randy S Schrecengost, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 14, 2018
In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183Randy S Schrecengost, Cecelia L Green, Yan Zhuang, et al.
Pharmaceutics|May 28, 2022
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade GliomaJulian S Rechberger, Kendra A Porath, Liang Zhang, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Cancer Letters|May 4, 2007
Pathways to tamoxifen resistanceRebecca B Riggins, Randy S Schrecengost, Michael S Guerrero, et al.
The Journal of Biological Chemistry|November 27, 2009
BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signalingNatasha R Schuh, Michael S Guerrero, Randy S Schrecengost, et al.
Cancer Research|November 1, 2008
A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cellsHuy Q Ta, Keena S Thomas, Randy S Schrecengost, et al.
Plos One|June 14, 2013
Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cellsAshley L Wilson, Randy S Schrecengost, Michael S Guerrero, et al.
Cancer Research|July 10, 2007
Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane rufflingRandy S Schrecengost, Rebecca B Riggins, Keena S Thomas, et al.
Cancers|May 11, 2024
Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma CellsLynn W Maines, Staci N Keller, Ryan A Smith, et al.
Molecular Cancer Research : MCR|August 15, 2015
Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer ProgressionRandy S Schrecengost, Staci N Keller, Matthew J Schiewer, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 16, 2004
Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1Kevin J French, Yan Zhuang, Randy S Schrecengost, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 14, 2018
In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183Randy S Schrecengost, Cecelia L Green, Yan Zhuang, et al.
Pharmaceutics|May 28, 2022
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade GliomaJulian S Rechberger, Kendra A Porath, Liang Zhang, et al.
Pageof 2